Kynurenic acid and schizophrenia.
Advances in experimental medicine and biology 2003 Sophie Erhardt, Lilly Schwieler, Göran Engberg
In recent years the "dopamine (DA) hypothesis of schizophrenia", has been modified into a more diversified view where an attenuated glutamatergic neurotransmission is believed to participate in the pathogenesis of the disease. Thus, schizophrenia may be regarded as a glutamate deficiency disorder. Kynurenic acid (KYNA) is an endogenous glutamate antagonist with a preferential action at the...